Ocular Therapeutix (OCUL) Retained Earnings (2013 - 2026)
Ocular Therapeutix's quarterly Retained Earnings came in at -$1.2 billion in Q1 2026, down 30.41% year-on-year from -$1.8 billion in Q1 2025, and down 7.66% quarter-over-quarter from -$1.2 billion in Q4 2025.
Ocular Therapeutix has reported Retained Earnings for 14 years, with the latest figure at -$1.2 billion in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 30.41% year-over-year to -$1.2 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.2 billion (down 30.41% YoY), and the FY2025 full-year result was -$1.2 billion, down 29.84% from the prior year.
- Retained Earnings for Q1 2026 stood at -$1.2 billion, down from -$1.2 billion in the prior quarter.
- The five-year high for Retained Earnings was -$558.3 million in Q1 2022, with the low at -$1.2 billion in Q1 2026.
- Average Retained Earnings over 5 years is -$812.4 million, with a median of -$762.4 million recorded in 2024.
- Year-over-year, Retained Earnings retreated 4.14% in 2022 and slumped 30.41% in 2026.
- Tracing OCUL's Retained Earnings over 5 years: stood at -$616.8 million in 2022, then decreased by 13.09% to -$697.6 million in 2023, then decreased by 27.74% to -$891.1 million in 2024, then slipped by 29.84% to -$1.2 billion in 2025, then fell by 7.66% to -$1.2 billion in 2026.
- The last three Retained Earnings figures came in at -$1.2 billion (Q1 2026), -$1.2 billion (Q4 2025), and -$1.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | -1.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.25 Bn |
| Dec 31, 2025 | -1.16 Bn |
| Sep 30, 2025 | -1.09 Bn |
| Jun 30, 2025 | -1.02 Bn |
| Mar 31, 2025 | -955.14 Mn |
| Dec 31, 2024 | -891.08 Mn |
| Sep 30, 2024 | -842.70 Mn |
| Jun 30, 2024 | -806.20 Mn |
| Mar 31, 2024 | -762.43 Mn |
| Dec 31, 2023 | -697.58 Mn |
| Sep 30, 2023 | -668.36 Mn |
| Jun 30, 2023 | -667.84 Mn |
| Mar 31, 2023 | -647.16 Mn |
| Dec 31, 2022 | -616.84 Mn |
| Sep 30, 2022 | -601.30 Mn |
| Jun 30, 2022 | -577.11 Mn |
| Mar 31, 2022 | -558.35 Mn |
| Dec 31, 2021 | -545.80 Mn |
| Sep 30, 2021 | -541.95 Mn |
| Jun 30, 2021 | -544.61 Mn |
| Mar 31, 2021 | -536.13 Mn |
| Dec 31, 2020 | -539.25 Mn |
| Sep 30, 2020 | -453.64 Mn |
| Jun 30, 2020 | -441.70 Mn |
| Mar 31, 2020 | -405.13 Mn |
| Dec 31, 2019 | -383.62 Mn |
| Sep 30, 2019 | -357.60 Mn |
| Jun 30, 2019 | -338.82 Mn |
| Mar 31, 2019 | -314.37 Mn |
| Dec 31, 2018 | -297.24 Mn |
| Sep 30, 2018 | -279.84 Mn |
| Jun 30, 2018 | -264.83 Mn |
| Mar 31, 2018 | -251.03 Mn |
| Dec 31, 2017 | -237.27 Mn |
| Sep 30, 2017 | -224.16 Mn |
| Jun 30, 2017 | -208.60 Mn |
| Mar 31, 2017 | -189.90 Mn |
| Dec 31, 2016 | -173.88 Mn |
| Sep 30, 2016 | 5,000.00 |
| Jun 30, 2016 | 10,000.00 |
| Mar 31, 2016 | -140.02 Mn |
| Dec 31, 2015 | -68,000.00 |
| Sep 30, 2015 | -118.54 Mn |
| Jun 30, 2015 | -107.02 Mn |
| Mar 31, 2015 | -97.01 Mn |
| Dec 31, 2014 | -89.43 Mn |
| Sep 30, 2014 | -81.47 Mn |
| Jun 30, 2014 | -74.18 Mn |
| Dec 31, 2013 | -60.78 Mn |